Bayer Alleges Patent Infringement Over Yaz
In the complaint filed Monday in the U.S. District Court for the District of Nevada, Bayer said Watson has submitted to the U.S. Food and Drug Administration an Abbreviated New Drug Application seeking approval to make a generic version of the Yaz tablet. Bayer said it was notified about the ANDA last month.
Yaz, a combination of drospirenone and ethinyl...
To view the full article, register now.